Stockscreener 앱 받기
13.73
0.66%
0.09
시간 외 거래:
13.73
전일 마감가:
$13.64
열려 있는:
$13.79
하루 거래량:
411.17K
Relative Volume:
0.42
시가총액:
$1.44B
수익:
-
순이익/손실:
$-115.88M
주가수익비율:
-8.8764
EPS:
-1.5468
순현금흐름:
$-104.72M
1주 성능:
-1.01%
1개월 성능:
-5.24%
6개월 성능:
-47.72%
1년 성능:
-36.11%
1일 변동 폭
$13.68
$14.08
1주일 범위
$13.30
$14.17
52주 변동 폭
$10.60
$38.12
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
EWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
13.73 | 1.46B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
why edgewise therapeutics inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplyQuick Profit Idea Stream - Newser
How Edgewise Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Why Edgewise Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - WV News
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment - MSN
(EWTX) Trading Report - news.stocktradersdaily.com
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpHere's What Happened - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by HC Wainwright - Defense World
HC Wainwright Initiates Edgewise Therapeutics With Buy Rating, $42 Price Target - MarketScreener
Edgewise Therapeutics (EWTX) Initiated with Buy Rating by HC Wainwright | EWTX Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder Drug - MSN
SG Americas Securities LLC Purchases New Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies - WV News
Edgewise Therapeutics stock falls after FDA deems data insufficient for accelerated approval - Investing.com UK
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.8%Here's What Happened - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stake Boosted by GAMMA Investing LLC - MarketBeat
Rhumbline Advisers Purchases 6,440 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $39.78 Average PT from Analysts - MarketBeat
Enliven to sell $200M in stock after positive drug trial - BizWest
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Transcript : Edgewise Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03 - MarketScreener
Bank of America Corp DE Has $1.31 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Ameriprise Financial Inc. Purchases Shares of 22,584 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Royal Bank of Canada Reaffirms Outperform Rating for Edgewise Therapeutics (NASDAQ:EWTX) - Defense World
Bank of America Corp DE Decreases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics (EWTX) Receives Reaffirmed 'Outperform' Ra - GuruFocus
RBC Capital maintains outperform rating on Edgewise Therapeutics stock By Investing.com - Investing.com India
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Invests $2.40 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference - Eastern Progress
Muscle Disease Leader Edgewise Therapeutics Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Two Sigma Investments LP Has $3.52 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
Certain Common Stock of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
(EWTX) Technical Data - news.stocktradersdaily.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Nuveen Asset Management LLC - MarketBeat
Polar Asset Management Partners Inc. Has $1.72 Million Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX) - Seeking Alpha
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.37%
자본화:
|
볼륨(24시간):